Ono Pharma's ONO-1110 misses primary endpoints in three Phase 2 pain studies

• Ono Pharmaceutical today announced plans for further ONO-1110 studies in postherpetic neuralgia, fibromyalgia and Hunner-type interstitial cystitis following pain-improvement signals.
• All three Phase 2 trials missed their primary endpoints; subgroup and exploratory analyses suggested pain relief.
• No further studies are planned in major depressive disorder or social anxiety disorder, where trials showed no efficacy signals.
• ONO-1110 demonstrated a favorable safety profile across all five studies.
• Detailed results will be presented at future conferences and through other appropriate channels.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ONO Pharmaceutical Co. Ltd. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.